

DLA
Dienstleistung
Lebensmittel
Analytik GbR

Evaluation Report
proficiency test

03/2016

Allergens III:

**β-Lactoglobulin, Casein and Gluten
in Infant Food**

Dienstleistung Lebensmittel Analytik GbR
Waldemar-Bonsels-Weg 170
22926 Ahrensburg, Germany

proficiency-testing@dla-lvu.de www.dla-lvu.de

Coordinator of this PT:
Dr. Matthias Besler

Inhalt / Content

| | |
|--|----|
| 1. Introduction..... | 3 |
| 2. Realisation..... | 3 |
| 2.1 Test material..... | 3 |
| 2.1.1 Homogeneity..... | 5 |
| 2.2 Sample shipment and information to the test..... | 6 |
| 2.3 Submission of results..... | 6 |
| 3. Evaluation..... | 7 |
| 3.1 Consensus value from participants (assigned value)..... | 7 |
| 3.2 Robust standard deviation..... | 8 |
| 3.3 Exclusion of results and outliers..... | 8 |
| 3.4 Target standard deviation (for proficiency assessment) . . . | 9 |
| 3.4.1 General model (Horwitz)..... | 9 |
| 3.4.2 Value by precision experiment..... | 9 |
| 3.4.3 Value by perception..... | 11 |
| 3.5 z-Score..... | 12 |
| 3.6 z'-Score..... | 13 |
| 3.7 Quotient S^*/σ | 13 |
| 3.8 Standard uncertainty of the assigned value..... | 13 |
| 3.9 Figures..... | 14 |
| 3.10 Recovery rates: Spiking..... | 14 |
| 4. Results..... | 15 |
| 4.1 Proficiency Test Milk..... | 17 |
| 4.1.1 ELISA-Results: β -Lactoglobulin..... | 17 |
| 4.1.2 ELISA-Results: Casein..... | 22 |
| 4.2 Proficiency Test Gluten..... | 27 |
| 4.2.1 ELISA-Results: Gluten..... | 27 |
| 4.2.2 PCR-Results: Gluten-containing Cereals..... | 33 |
| 5. Documentation..... | 34 |
| 5.1 Details by the participants..... | 34 |
| 5.1.1 ELISA: β -Lactoglobulin..... | 34 |
| 5.1.2 ELISA: Casein..... | 36 |
| 5.1.3 ELISA: Gluten..... | 38 |
| 5.1.4 PCR: Gluten-containing Cereals..... | 40 |
| 5.2 Homogeneity..... | 41 |
| 5.2.1 Mixture homogeneity before bottling..... | 41 |
| 6. Index of participant laboratories..... | 42 |
| 7. Index of references..... | 43 |

1. Introduction

The participation in proficiency testing schemes is an essential element of the quality-management-system of every laboratory testing food and feed, cosmetics and food contact materials. The implementation of proficiency tests enables the participating laboratories to prove their own analytical competence under realistic conditions. At the same time they receive valuable data regarding the verification and/or validation of the particular testing method [1, 5].

The purpose of DLA is to offer proficiency tests for selected parameters in concentrations with practical relevance.

Realisation and evaluation of the present proficiency test follows the technical requirements of DIN EN ISO/IEC 17043 (2010) and DIN ISO 13528:2009 / ISO 13528:2015 [2, 3].

2. Realisation

2.1 Test material

Two PT-samples for the detection of allergens in the range of mg/kg and one spiking material sample were provided for analysis. The spiking material sample contains the respective allergenic ingredients in the range of 1-10 % and was added to the spiked PT-sample. The results of the spiking material sample should give the possibility of a comparison with the spiked sample in respect to the detectability of the allergens with and without the influence of matrix and / or food processing.

The test material is an infant food mixture of a common in commerce "millet-pap" powder from 4th month and a "rice-pap" powder from 6th month (each labeled "milk and gluten free"). The basic composition of both sample A and sample B was the same (see table 1). After crushing, sieving and homogenisation of the basic mixture an aliquot of it was added stepwise during several homogenisations to the spiking material which contained the allergenic ingredients skimmed milk powder and wheat flour for preparation of sample B.

The composition of the spiking material sample and the amounts of allergens in sample B is given in table 2.

After homogenisation the samples were portioned to approximately 25 g into metallised PET film bags.

Table 1: Composition of DLA-Samples

| Ingredients | Sample A | Sample B |
|--|--------------|--------------|
| Organic-Millet-Pap with rice, infant pap after 4th month Ingredients: Millet whole flour (75%), rice whole flour (25%), vitamin B1 Nutrients per 100 g: Protein 11 g, carbohydrates 78 g, fat 3,7 g | 50,0 g/100 g | 48,5 g/100 g |
| Organic-Rice-Pap with corn and millet, infant pap after 6th month Ingredients: Rice whole flour (70%), corn flour (20%), millet whole flour (10%), vitamin B1 Nutrients per 100 g: Protein 8,6 g, carbohydrates 80 g, fat 2,8 g | 50,0 g/100 g | 48,5 g/100 g |
| Spiking material sample | - | 2,97 g/100 g |

Table 2: Added amounts of allergenic ingredients

| Ingredients | Spiking material sample | Amounts in Sample B |
|---|---|---|
| Potato flour Nutrients per 100g: Protein 0 g | 93 % | 2,76 % |
| <i>Milk:</i> - as Skimmed Milk Powder - thereof Total Protein - thereof Casein* - thereof β -Lactoglobulin* | 19600 mg/kg (1,96 %) 5740 mg/kg 4590 mg/kg 574 mg/kg | 582 mg/kg 192 mg/kg 154 mg/kg 19,2 mg/kg |
| <i>Wheat:</i> - as Wheat flour Type 1050 - thereof total protein* - thereof gluten** | 15300 mg/kg (1,53 %) 1840 mg/kg 1650 mg/kg | 349 mg/kg 41,8 mg/kg 37,6 mg/kg |
| Soy flour | 2,01 % | 0,060 % |
| Hazelnut spread | 1,18 % | 0,035 % |

* according to labelling and literature data

** Definition of "gluten" from the Gluten Intolerance Labelling Regulation (EU/41/2009) corresponds to 85-91% of wheat protein according to data from the literature

2.1.1 Homogeneity

The **mixture homogeneity before bottling** was examined 8-fold by **microtracer analysis**. It is a standardized method that is part of the international GMP certification system for feed [14].

Before mixing dye coated iron particles of μm size are added to the sample and the number of particles is determined after homogenization in taken aliquots. The evaluation of the mixture homogeneity is based on the Poisson distribution using the chi-square test. A probability of $\geq 5\%$ is equivalent to a good homogeneous mixture and of $\geq 25\%$ to an excellent mixture [14, 15].

The microtracer analysis of the present PT samples showed a probability of 43% for the spiking material sample and of 49% for the spiked sample B. Additionally particle number results were converted into concentrations, statistically evaluated according to normal distribution and compared to the standard deviation according to Horwitz. This gave a Hor-Rat value of 1,0 and 1,3 respectively. The results of microtracer analysis are given in the documentation.

The **homogeneity of bottled DLA-samples** (spiking material sample and spiked sample B) was checked by ELISA-test for gluten (fig. 1). The resulting standard deviations between the samples of $< 15\%$ ensured sufficient homogeneity [16, 17, 20, 21]. In case the criterion for sufficient homogeneity of the test items is not fulfilled the impact on the target standard deviation will be verified. If necessary the evaluation of results will be done considering the standard uncertainty of the assigned value (s. 3.8 and 3.11) [3].




Fig. 1: Testing of homogeneity of DLA-sample B and spiking material sample. Results are given in percent of the arithmetic mean

2.2 Sample shipment and information to the test

The portions of test material (sample A and sample B as well as the spiking material sample) were sent to every participating laboratory in the 7th week of 2016. The testing method was optional. The tests should be finished at April 1st 2016 the latest.

2.3 Submission of results

The participants submitted their results in standard forms, which have been sent by email or were available on our website. On one hand the results given as positive/negative and on the other hand the indicated results of the allergenic ingredients e.g. beta-lactoglobulin, casein or gluten in mg/kg were evaluated.

Queried and documented were the indicated results and details of the test methods like specificity, test kit manufacturer and hints about the procedure.

In case participants submitted several results for the same parameter obtained by different methods these results were evaluated with the same evaluation number with a letter as a suffix and indication of the related method.

One participant submitted the results delayed in agreement with DLA. All other participants submitted their results in time.

3. Evaluation

Different ELISA-methods for the determination of allergens in foods are eventually using different antibodies, are usually calibrated with different reference materials and may utilize differing extraction methods. Among others this can induce different results of the content of the analyte [23, 24, 25, 26]. It is for this reason that we contrast the results of the present proficiency test with several assigned values. Thereby it is possible to evaluate each single result in comparison to the mean of all results and/or in comparison to the mean of results obtained by a single method. For comparison the actually added amount is plotted in the figures of the results.

For quantitative results of the spiking material sample and the spiked sample recovery rates were calculated with respect to the known content of spiked allergens. The recovery rates were given for information only. No statistical evaluation was done. The recovery rates should exclusively give an estimation of the matrix- and/or processing influences.

PCR results were valuated qualitatively with respect to the percentages of positive and negative results, respectively. If there are ≥ 75 % positive or negative results, a consensus result is determined for each sample.

3.1 Consensus value from participants (assigned value)

The robust mean of the submitted results was used as assigned value (X_{pt}) („consensus value from participants“) providing a normal distribution. The calculation was done according to algorithm A as described in annex C of ISO 13528 [3].

The condition is that the majority of the participants' results show a normal distribution or are distributed unimodal and symmetrically. To this end, an examination of the distribution is carried out, inter alia, using the kernel density estimate [3, 12].

In case there are indications for sources of higher variability such as a bimodal distribution of results, a cause analysis is performed. Frequently different analytical methods may cause an anomaly in results' distribution. If this is the case, separate evaluations with own assigned values (X_{pti}) are made whenever possible.

If possible, this is the standard procedure for the evaluation of ELISA methods for the determination of allergens:

- i) **Robust mean of all results** - $X_{pt_{ALL}}$
- ii) **Robust mean of single methods** - $X_{pt_{METHOD i}}$
with at least 5 quantitative results given.

Single results giving values outside the measuring range of the participating laboratory or given as „0“ are not considered for statistical evaluation (e.g. results given as > 25 mg/kg and $< 2,5$ mg/kg, respectively) [3].

3.2 Robust standard deviation

For comparison to the target standard deviation σ_{pt} (standard deviation for proficiency assessment) a robust standard deviation (S^x) was calculated. The calculation was done according to algorithm A as described in annex C of ISO 13528 [3].

The following robust standard deviations were considered:

- i) **Robust standard deviation of all results** - S^x_{ALL}
- ii) **Robust standard deviation of single methods** - $S^x_{METHOD i}$
with at least 5 quantitative results given.

3.3 Exclusion of results and outliers

Before statistical evaluation obvious blunders, such as those with incorrect units, decimal point errors, and results for a another proficiency test item can be removed from the data set [2]. All results should be given at least with 2 significant digits. Specifying 3 significant digits is usually sufficient.

Results obtained by different analytical methods causing an increased variability and/or a bi- or multimodal distribution of results, are treated separately or could be excluded in case of too few numbers of results. For this results are checked by kernel density estimation [3, 12].

Results are identified as outliers by the use of robust statistics. If a value deviates from the robust mean by more than 3 times the robust standard deviation, it is classified as an outlier [3]. Detected outliers are stated for information only, when z-score are < -2 or > 2 . Due to the use of robust statistics outliers are not excluded, provided that no other reasons are present [3].

3.4 Target standard deviation (for proficiency assessment)

The target standard deviation of the assigned value σ_{pt} (= standard deviation for proficiency assessment) can be determined according to the following methods.

In the present PT the target standard deviation was determined according to 3.4.3 value by perception.

3.4.1 General model (Horwitz)

Based on statistical characteristics obtained in numerous PTs for different parameters and methods Horwitz has derived a general model for estimating the reproducibility standard deviation σ_R [6]. Later the model was modified by Thompson for certain concentration ranges [10]. The reproducibility standard deviation σ_R can be applied as the relative target standard deviation σ_{pt} in % of the assigned values and calculated according to the following equations [3]. For this the assigned value X_{pt} is used for the concentration c .

| Equations | Range of concentrations | corresponds to |
|-----------------------------|--|----------------------------------|
| $\sigma_R = 0,22c$ | $c < 1,2 \times 10^{-7}$ | $< 120 \mu\text{g}/\text{kg}$ |
| $\sigma_R = 0,02c^{0,8495}$ | $1,2 \times 10^{-7} \leq c \leq 0,138$ | $\geq 120 \mu\text{g}/\text{kg}$ |
| $\sigma_R = 0,01c^{0,5}$ | $c > 0,138$ | $> 13,8 \text{ g}/100\text{g}$ |

with c = mass content of analyte (as relative size, e.g. 1 mg/kg = 1 ppm = 10^{-6} kg/kg)

The target standard deviation according to Horwitz is currently not achievable by ELISA-methods for values in the mg/kg range and was therefore not considered for evaluation.

3.4.2 Value by precision experiment

Using the reproducibility standard deviation σ_R and the repeatability standard deviation σ_r of a precision experiment (collaborative trial or proficiency test) the target standard deviation σ_{pt} can be derived considering the number of replicate measurements m of participants in the present PT [3]:

$$\sigma_{pt} = \sqrt{\sigma_R^2 - \sigma_r^2 (m-1/m)}$$

Because in the present proficiency test the number of replicate measurements is $n = 1$, the reproducibility standard deviation σ_R is identical to the target standard deviation σ_{pt} .

The following table shows the relative reproducibility standard deviations from proficiency tests of ELISA-methods from German ASU §64 methods [27, 28, 29]:

| Method | Parameter | Matrix | Mean values | Relative σ_R | Literature |
|---------------------|-------------|-------------------|------------------|---------------------|------------|
| ELISA | Soy protein | Sausage | 0,36 - 4,07% | 14 - 28% | L 06.00-56 |
| ELISA (Manuf. A) | Peanut | Milk chocolate | 5,9 - 174 mg/kg | 20 - 31% | L 00.00-69 |
| ELISA (Manuf. B) | Peanut | Milk chocolate | 10,1 - 216 mg/kg | 14 - 32% | L 00.00-69 |
| ELISA (Manuf. A) | Peanut | Dark chocolate | 5,7 - 148 mg/kg | 22 - 33% | L 00.00-69 |
| ELISA (Manuf. A) | Hazelnut | Dark chocolate | 1,6 - 16,3 mg/kg | 12 - 33% | L 44.00-7 |
| ELISA (Manuf. A) | Hazelnut | Dark chocolate | 2,4 - 21,3 mg/kg | 14 - 19% | L 44.00-7 |

From these precision data of the ASU §64 methods the calculated relative target standard deviations are in the range of 12 - 33%.

Šturm et al. conducted two interlaboratory studies for the validation of commercial ELISA-Test-Kits for the determination of β -lactoglobulin and for the determination of casein [30, 31].

20 food samples with β -lactoglobulin contents in the range of 0 - 33 mg/kg were analyzed by 6 laboratories. Recovery rates ranged between 91 - 118%. Relative repeatability standard deviations ranged from 5,8 - 13% and the relative reproducibility standard deviations ranged from 26 - 49% [30].

Casein was analyzed by 8 laboratories in 10 food samples in the range of 0 - 30 mg/kg and in 3 food samples with contents >30 mg/kg. Recovery rates ranged between 67 - 81%. Relative repeatability standard deviations ranged from 11 - 52% and was for one sample Probe 99% and the relative reproducibility standard deviations ranged from 13 - 61% and were for two samples 96% and 111%, respectively [31].

According to the authors both ELISA-Test-Kits were acceptable for routine control of food samples [30, 31].

The Working Group on Prolamin Analysis and Toxicity (WGPAT) coordinated a collaborative study with two commercial ELISA-Test-Kits for the determination of gluten using the monoclonal R5 antibody [22]. 12 food samples with gliadin in the range of 0 - 168 mg/kg were analyzed by 20 laboratories. Recovery rates ranged between 65 and 110%, relative repeatability deviations ranged from 13 - 25% (method 1) and 11 - 22% (method 2) while the relative reproducibility standard deviations ranged from 23 - 47% (method 1) and 25 - 33% (method 2). According to the authors both ELISA-Test-Kits fulfilled therefore the current validation criteria for ELISA methods [22].

The IRMM (Institute for Reference Materials and Measurements) performed an interlaboratory comparison for five different ELISA-test kits for the quantification of peanut [25]. The mean values for two matrices were in

the concentration range of 0,3 - 16,1 mg/kg and 1,2 - 20,4 mg/kg, respectively. The lowest relative reproducibility standard deviations of the five test kits were for dark chocolate in the range of 20 - 42% and for cookies in the range of 23 - 61%.

3.4.3 Value by perception

The target standard deviation for proficiency assessment can be set at a value that corresponds to the level of performance that the coordinator would wish laboratories to be able to achieve [3].

Criteria for the level of performance of analytical methods for the quantitative determination of allergens in foods were recently elaborated e.g. by the Ministry of Health and Welfare (MHLW) in Japan [20], by the working group 12 „Food Allergens“ of the technical committee CEN/TC 275 [17-19], by an international "Food Allergen Working Group" under the advice of the AOAC Presidential Task Force on Food Allergens [21] and by the Codex Alimentarius Committee (CAC/GL 74-2010) [16].

Some of the relevant ELISA and PCR validation criteria of the mentioned panels are listed in tables 3 and 4, respectively.

Table 3: ELISA-Validation

| Literature [16-22] | Recovery rate | Repeatability standard deviation | Reproducibility standard deviation |
|-----------------------|---------------|-------------------------------------|---------------------------------------|
| MHLW 2006 | 50 - 150% | | ≤ 25% |
| CEN 2009 | | ≤ 20% | |
| AOAC 2010 | 50 - 150% | 6,9 - 34,4% ^(a) | 19,5 - 57,2 ^(a) |
| CAC 2010 | 70 - 120% | ≤ 25% | ≤ 35% |

(a) = Example from an hypothetical proficiency scheme in the range of 0,5 - 5 mg/kg

Table 4: PCR-Validation

| Literature [16] | Recovery rate | Repeatability standard deviation | Reproducibility standard deviation |
|--------------------|----------------------|-------------------------------------|---------------------------------------|
| CAC 2010 | ± 25% ^(a) | ≤ 25% | ≤ 35% |

(a) = Trueness / Richtigkeit

Based on the currently achievable level of performance of ELISA and PCR methods for the quantitative determination of allergens in foods, which could be deduced from the data of precision experiments and from validation criteria, we set a relative target standard deviation σ_{pt} of 25%.

This target standard deviation was applied for the statistical evaluation of the results by z-score and was used for all assigned values mentioned in 3.1.

3.5 z-Score

To assess the results of the participants the z-score is used. It indicates about which multiple of the target standard deviation (σ_{pt}) the result (x_i) of the participant is deviating from the assigned value (X_{pt}) [3].

Participants' z-scores are derived from:

$$z_i = \frac{(x_i - X_{pt})}{\sigma_{pt}}$$

The requirements for the analytical performance are generally considered as fulfilled if

$$-2 \leq z \leq 2 .$$

For information the z-scores below are calculated with a target standard deviation of 25%:

- i) **z-Score** - **z_{ALL}** (with respect to all methods)
- ii) **z-Score** - **z_{METHOD i}** (with respect to single methods)

3.5.1 Warning and action signals

In accordance with the norm ISO 13528 it is recommended that a result that gives rise to a z-score above 3,0 or below -3,0, shall be considered to give an "action signal" [3]. Likewise, a z-score above 2,0 or below -2,0 shall be considered to give a "warning signal". A single "action signal", or "warning signal" in two successive PT-rounds, shall be taken as evidence that an anomaly has occurred which requires investigation. For example a fault isolation or a root cause analysis through the examination of transmission error or an error in the calculation, in the trueness and precision must be performed and if necessary appropriate corrective measures should be applied [3].

In the figures of z-scores DLA gives the limits of warning and action signals as yellow and red lines respectively. According to ISO 13528 the signals are valid only in case of a number of ≥ 10 results [3].

3.6 z'-Score

The z'-score can be used for the valuation of the results of the participants, in cases the standard uncertainty has to be considered (s. 3.8). The z'-score represents the relation of the deviation of the result (x) of the participant from the respective consensus value (X) to the square root of quadrat sum of the target standard deviation ($\hat{\sigma}$) and the standard uncertainty ($U_{x_{pt}}$) [3].

The calculation is performed by:

$$z'_i = \frac{x_i - x_{pt}}{\sqrt{\sigma_{pt}^2 + u_{(x_{pt})}^2}}$$

If carried out an evaluation of the results by means of z 'score, we have defined below the expression in the denominator as a target standard deviation σ_{pt}' .

The requirements for the analytical performance are generally considered as fulfilled if

$$-2 \leq z' \leq 2 .$$

For warning and action signals see 3.6.1.

3.7 Quotient S^*/σ_{pt}

Following the HorRat-value the results of a proficiency-test (PT) can be considered convincing, if the quotient of robust standard deviation S^* and target standard deviation σ_{pt} does not exceed the value of 2.

A value > 2 means an insufficient precision, i.e. the analytical method is too variable, or the variation between the test participants is higher than estimated. Thus the comparability of the results is not given [3].

3.8 Standard uncertainty of the assigned value

Every assigned value has a standard uncertainty that depends on the analytical method, differences between the analytical methods used, the test material, the number of participating laboratories (P) and on other factors. The standard uncertainty ($U_{(x_{pt})}$) for this PT is calculated as follows [3]:

$$u_{(x_{pt})} = 1,25 \times \frac{s^*}{\sqrt{p}}$$

If $U_{(x_{pt})} \leq 0,3 \sigma_{pt}$ the standard uncertainty of the assigned value needs not to be included in the interpretation of the results of the PT [3].

Values exceeding 0,3 imply, that the target standard deviation could be too low with respect to the standard uncertainty of the assigned value. The Quotient $U(x_{pt})/\sigma_{pt}$ is reported in the characteristics of the test.

3.9 Figures

The assigned values and spiking levels are indicated as coloured lines in the figures of results. This allows the comparison of a single result with different possible target values like the spiked level, the robust mean of all results and the robust mean of a single method.

3.10 Recovery rates: Spiking

For the results of the spiking material sample and the spiked sample recovery rates were calculated with respect to the known content of added allergens. The related values of added allergens are given in 2.1 test material in table 2. As a range of acceptance RA for valuating participant's results the range of 50 - 150% for the recovery rates of allergen-ELISAs proposed by the AOAC was used [21]. For quantitative PCR determinations we use the same range of acceptance.

4. Results

All following tables are anonymized. With the delivering of the evaluation-report the participants are informed about their individual evaluation-number.

The following result sections are structured equally for the allergenic components. First all results for a certain analyte are reported together for sample A and afterwards for sample B.

To ensure the **comparability of quantitative results** DLA harmonized participants' results giving different specifications (e.g. as protein or as allergenic food) as far as possible.

ELISA-results given as gliadin were converted into gluten multiplying the gliadin-content with the factor of 2.

Evaluation was done separately for ELISA and PCR-techniques. The results were grouped according to the applied methods (e.g. test-kits) and sorted chronologically according to the evaluation-number of the participants.

Results were valuated qualitatively with respect to the percentages of positive and negative results, respectively. If there are $\geq 75\%$ positive or negative results, a consensus result is determined for each sample. Each participant result is valuated qualitatively with respect to the consensus value. The valuation was given as a percentage of results in agreement with the consensus values.

When there are at least 5 quantitative results for all methods or for single methods a statistical evaluation was done.

In cases when a statistical evaluation of the quantitative values was done the result table was given as indicated below:

| Evaluation number | Result | Result | z-Score $X_{pt_{ALL}}$ | z-Score $X_{pt_{M_i}}$ | Method | Remarks |
|-------------------|---------|---------|---------------------------|---------------------------|--------|---------|
| | pos/neg | [mg/kg] | | | | |

The statistical evaluation of results for each parameter was calculated in cases where at least 50% results were positive and at least 5 quantitative values were given:

| Characteristics | All Results [mg/kg] | Method i [mg/kg] |
|--|-------------------------------|----------------------------|
| Assigned value (X_{pt}) | $X_{pt_{ALL}}$ | $X_{pt_{METHOD\ i}}$ |
| <i>Number of results</i> | | |
| <i>Number of outliers</i> | | |
| Median | | |
| Robust mean (X_{pt}) | | |
| Robust standard deviation (S^*) | | |
| <i>Target data:</i> | | |
| Target standard deviation σ_{pt} | | |
| lower limit of target range ($X_{pt} - 2\sigma_{pt}$) | | |
| upper limit of target range ($X_{pt} + 2\sigma_{pt}$) | | |
| <i>Quotient S^*/σ_{pt}</i> | | |
| <i>Standard uncertainty $U(X_{pt})$</i> | | |
| <i>Quotient $U(X_{pt})/\sigma_{pt}$</i> | | |
| <i>Number of results in target range</i> | | |
| <i>Percent in target range</i> | | |

After that the recovery rates of the results for the spiking sample and the spiked sample are reported. The number of results within the range of acceptance of 50-150% is given.

4.1 Proficiency Test Milk

4.1.1 ELISA-Results: β -Lactoglobulin

Qualitative valuation of results: Samples A and B

| Evaluation number | Sample A | Sample A | Sample B | Sample B | Qualitative Valuation | Method | Remarks |
|-------------------|----------|----------|----------|----------|-----------------------|--------|----------------|
| | pos/neg | [mg/kg] | pos/neg | [mg/kg] | | | |
| 9 | negative | <5 | positive | 63 | 2/2 (100%) | BK | |
| 6 | negative | <0,1 | positive | 22 | 2/2 (100%) | ES | |
| 13 | negative | <0,2 | positive | 14,1 | 2/2 (100%) | ES | |
| 16 | negative | <0,1 | positive | 19 | 2/2 (100%) | ES | |
| 17 | negative | <0,05 | positive | >1 | 2/2 (100%) | ES | |
| 14 | negative | < 0,01 | positive | 20 | 2/2 (100%) | IL | |
| 1 | negative | <0.5 | positive | 5,91 | 2/2 (100%) | RS | |
| 2 | negative | < 0.5 | positive | 4,3 | 2/2 (100%) | RS | |
| 3 | negative | | positive | 6,9 | 2/2 (100%) | RS | |
| 4 | negative | <0,5 | positive | 31 | 2/2 (100%) | RS | outlier Xpt RS |
| 7 | negative | | positive | 8,6 | 2/2 (100%) | RS | |
| 8 | negative | <1 | positive | 1,8 | 2/2 (100%) | RS | |
| 15 | negative | <5 | positive | 8,3 | 2/2 (100%) | RS | |

| | Sample A | Sample B |
|------------------|----------|----------|
| Number positive | 0 | 13 |
| Number negative | 13 | 0 |
| Percent positive | 0 | 100 |
| Percent negative | 100 | 0 |
| Consensus value | negative | positive |

Methods :

BK = BioKits, Neogen
ES = ELISA Systems

IL = Immunolab
RS = Ridascreen®, R-Biopharm

Comments:

There were 100% negative results for sample A and 100% positive results for sample B by the ELISA-methods.

The consensus values are in agreement with the spiking of sample B.

Quantitative valuation of results: Sample B

| Evaluation number | β -Lactoglobulin [mg/kg] | z-Score X_{pt_ALL} | z-Score X_{pt_RS} | Method | Remarks |
|-------------------|-----------------------------------|--------------------------|-------------------------|--------|----------------|
| 9 | 63 | | | BK | |
| 6 | 22 | | | ES | |
| 13 | 14,1 | | | ES | |
| 16 | 19 | | | ES | |
| 17 | >1 | | | ES | |
| 14 | 20 | | | IL | |
| 1 | 5,91 | | -0,6 | RS | |
| 2 | 4,3 | | -1,5 | RS | |
| 3 | 6,9 | | 0,0 | RS | |
| 4 | 31 | | 13,8 | RS | outlier Xpt RS |
| 7 | 8,6 | | 0,9 | RS | |
| 8 | 1,8 | | -3,0 | RS | |
| 15 | 8,3 | | 0,8 | RS | |

Methods :

BK = BioKits, Neogen
ES = ELISA Systems

IL = Immunolab
RS = Ridascreen®, R-Biopharm




Fig. 2: Kernel Density Plot of all ELISA-results β -Lactoglobulin (with $h = \sigma_{pt}$ of X_{pt_ALL})

Comments:

The kernel density estimation shows a multimodal distribution due to differences of the applied methods: 1. method RS, 2. method ES and IL and 3. method BK. A shoulder at 31 mg/kg is caused by an outlier of method RS (s. fig. 2).

Characteristics: Quantitative evaluation β -Lactoglobulin**Sample B**

| Characteristics | All Results [mg/kg] | Method RS [mg/kg] |
|--|-------------------------------|-----------------------------|
| Assigned value (X_{pt}) | X_{ptALL} | $X_{ptMETHOD RS}$ |
| Number of results | 13 | 7 |
| Number of outliers | - | 1 |
| Median | 11,4 | 6,90 |
| Robust mean (X_{pt}) | 14,5 | 6,98 |
| Robust standard deviation (S^*) | 11,6 | 4,05 |
| <i>Target data:</i> | | |
| Target standard deviation σ_{pt} | | 1,75 |
| lower limit of target range ($X_{pt} - 2\sigma_{pt}$) | | 3,49 |
| upper limit of target range ($X_{pt} + 2\sigma_{pt}$) | | 10,5 |
| Quotient S^*/σ_{pt} | | 2,3 |
| Standard uncertainty $U(X_{pt})$ | | 1,91 |
| Quotient $U(X_{pt})/\sigma_{pt}$ | | 1,1 |
| Number of results in target range | | 6 |
| Percent in target range | | 86% |

Method:

RS = R-Biopharm, Ridascreen Fast®

Comments to the statistical characteristics:

The evaluation of all methods showed a multimodal distribution of results depending on testkit methods (see fig. 2). Therefore an evaluation of results across the methods was not performed.

The evaluation of results from method RS showed a slightly increased variability. The quotient S^*/σ_{pt} was above 2,0. The robust standard deviation is in the range of established values for the reproducibility standard deviation of the applied method (see 3.4.2 value by precision experiments and 3.4.3 value by perception). The comparability of results is given.

The robust mean of the evaluation of method RS was 32% of the spiking level of β -lactoglobulin to sample B fulfilling the recommendations for the applied methods (s. 3.4.3 and "Recovery rates of β -Lactoglobulin" p. 21).




Fig. 3: ELISA-Results β -Lactoglobulin
 green line = Spiking level
 red line = Assigned value robust mean all results
 blue line = Assigned value robust mean results method RS
 round symbols = Applied methods (see legend)




Fig. 4: z-Scores (ELISA-Results as β -Lactoglobulin)
 Assigned value robust mean of method RS (R-Biopharm, Ridascreen)

**Recovery Rates for β -Lactoglobulin:
Spiking Material Sample and Sample B**

| Evaluation number | Spiking material | Recovery rate | Sample B | Recovery rate | Method | Remarks |
|-------------------|------------------|---------------|----------|---------------|--------|----------------|
| | [mg/kg] | [%] | [mg/kg] | [%] | | |
| 9 | 1150 | 200 | 63 | 328 | BK | |
| 6 | 330 | 57 | 22 | 115 | ES | |
| 13 | NA | | 14,1 | 73 | ES | |
| 16 | 410 | 71 | 19 | 99 | ES | |
| 17 | | | >1 | | ES | |
| 14 | 396 | 69 | 20 | 104 | IL | |
| 1 | 315 | 55 | 5,91 | 31 | RS | |
| 2 | | | 4,3 | 22 | RS | |
| 3 | >13.5 | | 6,9 | 36 | RS | |
| 4 | 1400 | 244 | 31 | 161 | RS | outlier Xpt RS |
| 7 | 280 | 49 | 8,6 | 45 | RS | |
| 8 | | | 1,8 | 9 | RS | |
| 15 | 472 | 82 | 8,3 | 43 | RS | |

| RA* | 50-150 % | RA* | 50-150 % |
|---------------|----------|---------------|----------|
| Number in RA | 5 | Number in RA | 4 |
| Percent in RA | 63 | Percent in RA | 33 |

* Range of acceptance of AOAC for allergen ELISAS

Recovery rate

100% relative size:
beta-Lactoglobulin, s. page 4

Methods :

BK = BioKits, Neogen
ES = ELISA Systems

IL = Immunolab
RS = Ridascreen®, R-Biopharm

Comments:

For the spiking material sample 63% of the participants obtained a recovery rate within the range of the AOAC-recommendation of 50-150%. For the infant food-sample B produced with the spiking material sample 33% of the recovery rates were in the range of acceptance.

4.1.2 ELISA-Results: Casein**Qualitative valuation of results: Samples A and B**

| Evaluation number | Sample A | Sample A | Sample B | Sample B | Qualitative Valuation | Method | Remarks |
|-------------------|----------|----------|----------|----------|-----------------------|--------|---------|
| | pos/neg | [mg/kg] | pos/neg | [mg/kg] | | | |
| 17 | negative | <1 | positive | >30 | 2/2 (100%) | 4L | |
| 2 | negative | < 0.2 | positive | | 2/2 (100%) | AQ | |
| 9 | positive | 0,55 | positive | 313 | 1/2 (50%) | AQ | |
| 12 | negative | <1 | positive | 435,9 | 2/2 (100%) | AQ | |
| 16 | negative | <0,2 | positive | 450 | 2/2 (100%) | AQ | |
| 10 | negative | < 2,5 | positive | 475 | 2/2 (100%) | BK | |
| 13 | negative | <0,6 | positive | 64,6 | 2/2 (100%) | ES | |
| 14 | negative | < 0,1 | positive | 250 | 2/2 (100%) | IL | |
| 1 | negative | <2.5 | positive | 100,58 | 2/2 (100%) | RS | |
| 3 | negative | | positive | 55,7 | 2/2 (100%) | RS | |
| 4 | negative | <2,5 | positive | 36 | 2/2 (100%) | RS | |
| 6 | negative | <2,5 | positive | 155 | 2/2 (100%) | RS | |
| 7 | negative | | positive | 176,3 | 2/2 (100%) | RS | |
| 8 | negative | <0,5 | positive | 269,7 | 2/2 (100%) | RS | |
| 11 | negative | | positive | 254 | 2/2 (100%) | RS | |
| 15 | negative | <5 | positive | 353,6 | 2/2 (100%) | RS | |

| | Sample A | Sample B |
|------------------|----------|----------|
| Number positive | 1 | 16 |
| Number negative | 15 | 0 |
| Percent positive | 6 | 100 |
| Percent negative | 94 | 0 |
| Consensus value | negative | positive |

Methods :

4L = 4LabDiagnostics

AQ = AgraQuant, RomerLabs

BK = BioKits, Neogen

ES = ELISA Systems

IL = Immunolab

RS = Ridascreen®, R-Biopharm

Comments:

There were 94% negative results for sample A and 100% positive results for sample B by the ELISA-methods. The positive result for sample A was in the range of the limit of detection and quantification of the respective method.

The consensus values are in agreement with the spiking of sample B.

Quantitative valuation of results: Sample B

| Evaluation number | Casein [mg/kg] | z-Score Xpt _{ALL} | z'-Score Xpt _{RS} | Method | Remarks |
|-------------------|-------------------|-------------------------------|-------------------------------|--------|---------|
| 17 | >30 | | | 4L | |
| 2 | | | | AQ | |
| 9 | 313 | | | AQ | |
| 12 | 435,9 | | | AQ | |
| 16 | 450 | | | AQ | |
| 10 | 475 | | | BK | |
| 13 | 64,6 | | | ES | |
| 14 | 250 | | | IL | |
| 1 | 100,58 | | -1,7 | RS | |
| 3 | 55,7 | | -2,7 | RS | |
| 4 | 36 | | -3,2 | RS | |
| 6 | 155 | | -0,5 | RS | |
| 7 | 176,3 | | 0,0 | RS | |
| 8 | 269,7 | | 2,2 | RS | |
| 11 | 254 | | 1,8 | RS | |
| 15 | 353,6 | | 4,1 | RS | |

Methods :

4L = 4LabDiagnostics
 AQ = AgraQuant, RomerLabs
 BK = BioKits, Neogen

ES = ELISA Systems
 IL = Immunolab
 RS = Ridascreen®, R-Biopharm




Fig. 5: Kernel Density Plot of all ELISA-results Casein (with $h = \sigma_{pt}$ of $X_{pt_{ALL}}$)

Comments:

The kernel density estimation shows a broad distribution of results with modalities, which could not clearly attributed the applied methods: method AQ showed higher results, while the results of method RS were distributed over a broader range. There were only one quantitative result each from the methods BK, ES and IL (s. fig. 5).

Characteristics: Quantitative evaluation Casein**Sample B**

| Characteristics | All Results [mg/kg] | Method RS [mg/kg] |
|---|-------------------------------|-----------------------------|
| Assigned value (X_{pt}) | X_{ptALL} | $X_{ptMETHOD RS}$ |
| Number of results | 14 | 8 |
| Number of outliers | - | 0 |
| Median | 252 | 166 |
| Robust mean (X_{pt}) | 242 | 175 |
| Robust standard deviation (S^*) | 171 | 126 |
| <i>Target data:</i> | | |
| Target standard deviation σ_{pt}' | | 70,9 |
| lower limit of target range ($X_{pt} - 2\sigma_{pt}'$) | | 33,4 |
| upper limit of target range ($X_{pt} + 2\sigma_{pt}'$) | | 317 |
| Quotient S^*/σ_{pt}' | | 1,8 |
| Standard uncertainty $U(X_{pt})$ | | 55,7 |
| Quotient $U(X_{pt})/\sigma_{pt}'$ | | 0,79 |
| Number of results in target range | | 7 |
| Percent in target range | | 88% |

Method:

RS = R-Biopharm, Ridascreen Fast®

Comments to the statistical characteristics:

The evaluation of all methods showed a multimodal distribution of results depending on testkit methods (see fig. 2). Therefore an evaluation of results across the methods was not performed.

The evaluation of results from method RS showed an increased variability. The robust standard deviation is above the range of established values for the reproducibility standard deviation of the applied method (see 3.4.2 value by precision experiments and 3.4.3 value by perception). The quotient S^*/σ_{pt}' was clearly above 2,0. Therefore evaluation was performed by z'-score considering the standard uncertainty. The resulting quotient S^*/σ_{pt}' was below 2,0 (see 3.6 to 3.8).

The robust mean of the evaluation of method RS was approximately 114% of the spiking level of casein to sample B fulfilling the recommendations for the applied methods (s. 3.4.3 and "Recovery rates of Casein" p. 26).




Fig. 6: ELISA-Results Casein
 green line = Spiking level
 red line = Assigned value robust mean all results
 blue line = Assigned value robust mean results method RS
 round symbols = Applied methods (see legend)




Fig. 7: z'-Scores (ELISA-Results as Casein)
 Assigned value robust mean of method RS (R-Biopharm, Ridascreen)

**Recovery Rates for Casein:
Spiking Material Sample and Sample B**

| Evaluation number | Spiking material | Recovery rate | Sample B | Recovery rate | Method | Remarks |
|-------------------|------------------|---------------|----------|---------------|--------|---------|
| | [mg/kg] | [%] | [mg/kg] | [%] | | |
| 17 | | | >30 | | 4L | |
| 2 | | | | | AQ | |
| 9 | 8873 | 193 | 313 | 203 | AQ | |
| 12 | >3750 | | 435,9 | 283 | AQ | |
| 16 | 13000 | 283 | 450 | 292 | AQ | |
| 10 | 19000 | 414 | 475 | 308 | BK | |
| 13 | NA | | 64,6 | 42 | ES | |
| 14 | 5900 | 129 | 250 | 162 | IL | |
| 1 | 4194 | 91 | 100,58 | 65 | RS | |
| 3 | >67.5 | | 55,7 | 36 | RS | |
| 4 | 4300 | 94 | 36 | 23 | RS | |
| 6 | 8500 | 185 | 155 | 101 | RS | |
| 7 | 8324 | 181 | 176,3 | 114 | RS | |
| 8 | | | 269,7 | 175 | RS | |
| 11 | 6460 | 141 | 254 | 165 | RS | |
| 15 | 8462,5 | 184 | 353,6 | 230 | RS | |

| RA* | 50-150 % | RA* | 50-150 % |
|---------------|-----------|---------------|-----------|
| Number in RA | 4 | Number in RA | 3 |
| Percent in RA | 40 | Percent in RA | 21 |

Recovery rate
100% relative size:
Casein, s. page 4

* Range of acceptance of AOAC for allergen ELISAS

Methods :

BK = BioKits, Neogen
ES = ELISA Systems

IL = Immunolab
RS = Ridascreen®, R-Biopharm

Comments:

For the spiking material sample 40% (4) of the participants obtained a recovery rate within the range of the AOAC-recommendation of 50-150%. For the infant food-sample B produced with the spiking material sample 21% (3) of the recovery rates were in the range of acceptance.

4.2 Proficiency Test Gluten

4.2.1 ELISA-Results: Gluten

Qualitative valuation of results: Samples A and B

Methods:

| Evaluation number | Sample A | Sample A | Sample B | Sample B | Qualitative Valuation | Method | Remarks |
|-------------------|----------|----------|----------|----------|-----------------------|--------|--------------------|
| | pos/neg | [mg/kg] | pos/neg | [mg/kg] | | | |
| 7 | positive | 19,2 | positive | 78,8 | 1/2 (50%) | AQ | |
| 14 | negative | < 1 | positive | 100 | 2/2 (100%) | IL | Result converted * |
| 1 | negative | <5 | positive | 43,77 | 2/2 (100%) | RS | |
| 2 | negative | < 5 | positive | 45,2 | 2/2 (100%) | RS | |
| 3 | negative | | positive | 40,8 | 2/2 (100%) | RS | |
| 4 | negative | <5 | positive | 33 | 2/2 (100%) | RS | |
| 6 | negative | <7 | positive | 35 | 2/2 (100%) | RS | |
| 8 | negative | <5 | positive | 69 | 2/2 (100%) | RS | |
| 9 | negative | <5 | positive | 17 | 2/2 (100%) | RS | |
| 12 | negative | <5 | positive | 26,22 | 2/2 (100%) | RS | |
| 13 | negative | <5 | positive | 38,1 | 2/2 (100%) | RS | |
| 15 | negative | <0,25 | positive | 44,1 | 2/2 (100%) | RS | |
| 16 | negative | <5 | positive | 41 | 2/2 (100%) | RS | |
| 17 | negative | <3 | positive | 21,9 | 2/2 (100%) | RS | |
| 10 | negative | < 5 | positive | 61,4 | 2/2 (100%) | VT | |
| 16 | negative | <10 | positive | 67 | 2/2 (100%) | VT | |

* calculation see p. 15

| | Sample A | Sample B |
|------------------|----------|----------|
| Number positive | 1 | 16 |
| Number negative | 15 | 0 |
| Percent positive | 6 | 100 |
| Percent negative | 94 | 0 |
| Consensus value | negative | positive |

AQ = AgraQuant, RomerLabs
IL = Immunolab

RS = Ridascreen®, R-Biopharm
VT = Veratox, Neogen

Comments:

There were 94% negative results for sample A and 100% positive results for sample B by the ELISA-methods. One positive result for sample A was obtained by method AQ (AgraQuant G12). According to the manufacturer the testkit detects prolamines from oat (in contrast to the other methods). The two PCR results of method Sure Food Gluten, which detects oat as well according to the testkit manual, are positive and negative for sample A. The presence of oat traces in the sample could not be excluded.

The consensus values are in qualitative agreement with the spiking of sample B.

Quantitative valuation of results: Sample B

| Evaluation number | Gluten [mg/kg] | z-Score Xpt _{ALL} | z-Score Xpt _{RS} | Method | Remarks |
|-------------------|-------------------|-------------------------------|------------------------------|--------|--------------------|
| 7 | 78,8 | 2,8 | | AQ | |
| 14 | 100 | 4,6 | | IL | Result converted * |
| 1 | 43,77 | -0,2 | 0,7 | RS | |
| 2 | 45,2 | -0,1 | 0,9 | RS | |
| 3 | 40,8 | -0,5 | 0,4 | RS | |
| 4 | 33 | -1,2 | -0,4 | RS | |
| 6 | 35 | -1,0 | -0,2 | RS | |
| 8 | 69 | 2,0 | 3,5 | RS | |
| 9 | 17 | -2,5 | -2,2 | RS | |
| 12 | 26,22 | -1,7 | -1,2 | RS | |
| 13 | 38,1 | -0,7 | 0,1 | RS | |
| 15 | 44,1 | -0,2 | 0,8 | RS | |
| 16 | 41 | -0,5 | 0,4 | RS | |
| 17 | 21,9 | -2,1 | -1,6 | RS | |
| 10 | 61,4 | 1,3 | | VT | |
| 16 | 67 | 1,8 | | VT | |

* calculation see p. 15

Methods :

AQ = AgraQuant, RomerLabs
 IL = Immunolab

RS = Ridascreen®, R-Biopharm
 VT = Veratox, Neogen




Fig. 8: Kernel Density Plot of all ELISA-results gluten (with $h = \sigma_{pt}$ of X_{ptALL})

Comment:

The kernel density estimation shows a normal distribution of results with two slight shoulders at 60-80 mg/kg (methods AQ a. VT) and 100 mg/kg (method IL) (s. fig. 8).

Characteristics: Quantitative evaluation Gluten**Sample B**

| Characteristics | All Results [mg/kg] | Method RS [mg/kg] |
|--|-------------------------------|-----------------------------|
| Assigned value (X_{pt}) | $X_{pt_{ALL}}$ | $X_{pt_{METHOD RS}}$ |
| Number of results | 16 | 12 |
| Number of outliers | 0 | 0 |
| Median | 42,4 | 39,5 |
| Robust mean (X_{pt}) | 46,3 | 36,9 |
| Robust standard deviation (S^*) | 21,9 | 11,7 |
| <i>Target data:</i> | | |
| Target standard deviation σ_{pt} | 11,6 | 9,23 |
| lower limit of target range ($X_{pt} - 2\sigma_{pt}$) | 23,2 | 18,5 |
| upper limit of target range ($X_{pt} + 2\sigma_{pt}$) | 69,5 | 55,4 |
| Quotient S^*/σ_{pt} | 1,9 | 1,3 |
| Standard uncertainty $U(X_{pt})$ | 6,86 | 4,24 |
| Quotient $U(X_{pt})/\sigma_{pt}$ | 0,59 | 0,46 |
| Number of results in target range | 11 | 11 |
| Percent in target range | 69% | 92% |

Method:

RS = R-Biopharm, Ridascreen®

Comments to the statistical characteristics:

The evaluation of all methods and the evaluation of results from method RS showed a normal to low variability of results, respectively. The quotients S^*/σ_{pt} were below 2,0. The robust standard deviation is in the range of established values for the reproducibility standard deviation of the applied methods (see 3.4.2 value by precision experiments and 3.4.3 value by perception). The comparability of results is given. This conclusion is limited for the evaluation across the methods, because there are only a few results for the methods AQ, IL and VT. All of these results were above the robust mean of all methods.

The robust means of the evaluations were 123% and 98% of the spiking level of gluten to sample B and within the recommendations for the applied methods (s. 3.4.3 and "Recovery rates of Gluten" p.32).




Fig. 9: ELISA-Results Gluten
 green line = Spiking level
 red line = Assigned value robust mean all results
 blue line = Assigned value robust mean results method RS
 round symbols = Applied methods (see legend)




Fig. 10: z-Scores (ELISA-Results as Gluten)
 Assigned value robust mean of all results




Fig. 11: z-Scores (ELISA-Results as Gluten)
Assigned value robust mean of method RS
(R-Biopharm, Ridascreen)

**Recovery Rates for Gluten:
Spiking Material Sample and Sample B**

| Evaluation number | Spiking material | Recovery rate | Sample B | Recovery rate | Method | Remarks |
|-------------------|------------------|---------------|----------|---------------|--------|--------------------|
| | [mg/kg] | [%] | [mg/kg] | [%] | | |
| 7 | 1035 | 63 | 78,8 | 210 | AQ | |
| 14 | 2940 | 178 | 100 | 266 | IL | Result converted * |
| 1 | 934 | 57 | 43,77 | 116 | RS | |
| 2 | | | 45,2 | 120 | RS | |
| 3 | >320 | | 40,8 | 109 | RS | |
| 4 | 11021 | 668 | 33 | 88 | RS | |
| 6 | 785 | 48 | 35 | 93 | RS | |
| 8 | | | 69 | 184 | RS | |
| 9 | 375 | 23 | 17 | 45 | RS | |
| 12 | 735,34 | 45 | 26,22 | 70 | RS | |
| 13 | NA | | 38,1 | 101 | RS | |
| 15 | 1501,3 | 91 | 44,1 | 117 | RS | |
| 16 | 750 | 45 | 41 | 109 | RS | |
| 17 | | | 21,9 | 58 | RS | |
| 10 | | | 61,4 | 163 | VT | |
| 16 | - | | 67 | 178 | VT | |

* calculation see p. 15

| RA* | 50-150 % | RA* | 50-150 % |
|---------------|-----------|---------------|-----------|
| Number in RA | 3 | Number in RA | 10 |
| Percent in RA | 33 | Percent in RA | 63 |

Recovery rate
100% relative size:
Gluten, s. page 4

* Range of acceptance of AOAC for allergen ELISAS

Methods :

AQ = AgraQuant, RomerLabs
IL = Immunolab

RS = Ridascreen®, R-Biopharm
VT = Veratox, Neogen

Comments:

For the spiking material sample 33% (3) of the participants obtained a recovery rate within the range of the AOAC-recommendation of 50-150%. For the infant food-sample B produced with the spiking material sample 63% of the recovery rates were in the range of acceptance.

4.2.2 PCR-Results: Gluten-containing Cereals

| Evaluation number | Result Sample A | Result Sample A | Result Sample B | Result Sample B | Qualitative Valuation | Method | Remarks |
|-------------------|-----------------|-----------------|-----------------|-----------------|--------------------------------|--------|---------|
| | pos / neg | mg/kg | pos / neg | mg/kg | Agreement with Consensus Value | | |
| 3 | positive | | positive | | - | SFA | |
| 17 | negative | | positive | | - | SFA | |
| 16 | negative | | positive | | - | div | |

Methods:

SFA = Sure Food Allergen,
R-Biopharm / Congen

div = not indicated / other method

Comments:

There were 3 positive results for sample B for gluten-containing cereal-DNA by the PCR-methods. The results are in agreement with the spiking of sample B.

For sample A there were one positive and two negative results. Among the ELISA results was one positive result as well (see p.27).

5. Documentation

Details by the participants

5.1 Details by the participants

5.1.1 ELISA: β -Lactoglobulin

Primary data

| Evaluation number | Result Sample A | | Result Sample B | | Result Spiking Sample | | quantitative Result given as | Meth. Abr. | Method |
|-------------------|-----------------|--------|-----------------|-------|-----------------------|-------|------------------------------|------------|--|
| | qualitative | mg/kg | qualitative | mg/kg | qualitative | mg/kg | | | |
| 9 | negative | <5 | positive | 63 | positive | 1150 | beta-Lactoglobulin | BK | BioKits β -Lactoglobulin Assay Kit, Neogen |
| 6 | negative | <0,1 | positive | 22 | positive | 330 | beta-Lactoglobulin | ES | ELISA-Systems β -Lactoglobulin Residue Detection ELISA |
| 13 | negative | <0,2 | positive | 14,1 | NA | NA | beta-Lactoglobulin | ES | ELISA-Systems β -Lactoglobulin Residue Detection ELISA |
| 16 | negative | <0,1 | positive | 19 | positive | 410 | beta-Lactoglobulin | ES | ELISA-Systems β -Lactoglobulin Residue Detection ELISA |
| 17 | negative | <0,05 | positive | >1 | - | | Given as | ES | ELISA-Systems β -Lactoglobulin Residue Detection ELISA |
| 14 | negative | < 0,01 | positive | 20 | positive | 396 | beta-Lactoglobulin | IL | Immunolab β -Lactoglobulin ELISA |
| 1 | negative | <0.5 | positive | 5,91 | positive | 315 | beta-Lactoglobulin | RS | Ridascreen Fast β -Lactoglobulin (R4902), r-Biopharm |
| 2 | negative | < 0.5 | positive | 4,3 | - | | beta-Lactoglobulin | RS | Ridascreen Fast β -Lactoglobulin (R4902), r-Biopharm |
| 3 | negative | | positive | 6,9 | positive | >13.5 | beta-Lactoglobulin | RS | Ridascreen Fast β -Lactoglobulin (R4902), r-Biopharm |
| 4 | negative | <0,5 | positive | 31 | positive | 1400 | beta-Lactoglobulin | RS | Ridascreen Fast β -Lactoglobulin (R4902), r-Biopharm |
| 7 | negative | | positive | 8,6 | positive | 280 | beta-Lactoglobulin | RS | Ridascreen Fast β -Lactoglobulin (R4902), r-Biopharm |
| 8 | - | <1 | - | 1,8 | - | | beta-Lactoglobulin | RS | Ridascreen Fast β -Lactoglobulin (R4902), r-Biopharm |
| 15 | - | <5 | - | 8,3 | - | 472 | β -Lactoglobulin | RS | r-biopharm, RIDASCREEN®FAST β -Lactoglobulin (R4902) |

Methods :

BK = BioKits, Neogen
ES = ELISA Systems

IL = Immunolab
RS = Ridascreen®, R-Biopharm

Other details to the Methods

| Evaluation number | Meth. Abk. | Specifity | Remarks to the Method (Extraction and Determination) | Further Remarks |
|-------------------|------------|--|--|---|
| | | Antibody | e.g. Extraction Solution / Time / Temperature | |
| 9 | BK | | | |
| 6 | ES | | | |
| 13 | ES | β -Lactoglobulin | Manufacturer's extraction solution / 15 min / 60C | |
| 16 | ES | | | |
| 17 | ES | | | |
| 14 | IL | | | |
| 1 | RS | As stated in the kit | As per kit instructions | Sample solidified upon addition of primary extraction solution. To produce a liquid mix, half the amount of secondary extraction solution was added 1 stage early and the remaining amount of solution was added at the second stage. |
| 2 | RS | | | |
| 3 | RS | | | |
| 4 | RS | | | |
| 7 | RS | | | |
| 8 | RS | Monoclonal específico de beta-lactoglobulina | Solución de Extracción 2/10min/100°C +A-AEP/10min/60°C | |
| 15 | RS | | As per kit instructions | |

5.1.2 ELISA: Casein*Primary data*

| Evaluation number | Result Sample A | | Result Sample B | | Result Spiking Sample | | quantitative Result given as | Meth. Abr. | Method |
|-------------------|-----------------|-----------|-----------------|---------|-----------------------|--------|--|------------|--|
| | qualitative | mg/kg | qualitative | mg/kg | qualitative | mg/kg | | | |
| 17 | negative | <1 | positive | >30 | - | | e.g. food / food protein Ergebnis als | 4L | Test-Kit + Manufacturer Kit 4LAB MLK ALERT II |
| 2 | negative | < 0.2 | positive | | - | | Casein | AQ | AgraQuant Casein (CO-KAL1200), RomerLabs |
| 9 | positive | 0,55 | positive | 313 | positive | 8873 | Casein | AQ | AgraQuant Casein (CO-KAL1200), RomerLabs |
| 12 | negative | <1 | positive | 435,9 | positive | >3750 | Casein | AQ | AgraQuant Casein (CO-KAL1200), RomerLabs |
| 16 | negative | <0,2 | positive | 450 | positive | 13000 | Casein | AQ | AgraQuant Casein (CO-KAL1200), RomerLabs |
| 10 | negative | < 2,5 ppm | positive | 475 ppm | positive | 1,90% | Casein | BK | BioKits Casein Assay Kit, Neogen |
| 13 | negative | <0,6 | positive | 64,6 | NA | NA | Casein | ES | ELISA-Systems Casein Residue Detection ELISA |
| 14 | negative | < 0,1 | positive | 250 | positive | 5900 | Casein | IL | Immunolab Casein ELISA |
| 1 | negative | <2.5 | positive | 100,58 | positive | 4194 | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 3 | negative | | positive | 55,7 | positive | >67.5 | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 4 | negative | <2,5 | positive | 36 | positive | 4300 | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 6 | negative | <2,5 | positive | 155 | positive | 8500 | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 7 | negative | | positive | 176,3 | positive | 8324 | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 8 | - | <0,5 | - | 269,7 | - | | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 11 | negative | | - | 254 | - | 6460 | Casein | RS | Ridascreen Fast Casein (R4612), r-Biopharm |
| 15 | - | <5 | - | 353,6 | - | 8462,5 | Casein | RS | r-biopharm, RIDASCREEN®FAST Casein (R4612) |

Methods :

4L = 4LabDiagnostics

AQ = AgraQuant, RomerLabs

BK = BioKits, Neogen

ES = ELISA Systems

IL = Immunolab

RS = Ridascreen®, R-Biopharm

Other details to the methods

| Evaluation number | Meth. Abr. | Specificity | Remarks to the Method (Extraction and Determination) | Further Remarks |
|-------------------|------------|----------------------|---|--|
| | | Antibody | e.g. Extraction Solution / Time / Temperature | |
| 17 | 4L | | | |
| 2 | AQ | | | |
| 9 | AQ | | | |
| 12 | AQ | Casein | Extraction solution / 15 min / 60°C | Spiking sample: 1:4000; sample A/B: 1:500; |
| 16 | AQ | | | |
| 10 | BK | Casein | | applied Veratox Casein Allergen |
| 13 | ES | Casein | Manufacturer's extraction solution / 15 min / 60C | |
| 14 | IL | | | |
| 1 | RS | As stated in the kit | As per kit instructions | Sample solidified upon addition of primary extraction solution. To produce a liquid mix, half the amount of secondary extraction solution was added 1 stage early and the remaining amount of solution was added at the secondary stage. |
| 3 | RS | | | |
| 4 | RS | | | |
| 6 | RS | | | |
| 7 | RS | | sample preparation for infant food (with AEP), LOQ 0,5ppm | |
| 8 | RS | specific for casein | Allergen extraction buffer diluted/10min/60°C | |
| 11 | RS | Casein | | |
| 15 | RS | | As per kit instructions | |

5.1.3 ELISA: Gluten*Primary data*

| Evaluation number | Result Sample A | | Result Sample B | | Result Spiking Sample | | quantitative Result given as e.g. food / food protein | Meth. Abr. | Method |
|-------------------|-----------------|---------|-----------------|----------|-----------------------|--------|--|------------|---|
| | qualitative | mg/kg | qualitative | mg/kg | qualitative | mg/kg | | | |
| 7 | positive | 19,2 | positive | 78,8 | positive | 1035 | Gluten | AQ | AgraQuant Gluten G12, RomerLabs |
| 14 | negative | < 1 | positive | 50 | positive | 1470 | Gluten | IL | Immunolab Gliadin GLU-E02 |
| 1 | negative | <5 | positive | 43,77 | positive | 934 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 2 | negative | < 5 | positive | 45,2 | positive | | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 3 | negative | | positive | 40,8 | positive | >320 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 4 | negative | <5 | positive | 33 | positive | 11021 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 6 | negative | <7 | positive | 35 | positive | 785 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 8 | - | <5 | - | 69 | - | | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 9 | negative | <5 | positive | 17 | positive | 375 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 12 | negative | <5 | positive | 26,22 | positive | 735,34 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 13 | negative | <5 | positive | 38,1 | NA | NA | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 15 | - | <0,25 | - | 44,1 | - | 1501,3 | Gluten | RS | r-biopharm, RIDASCREEN®FAST Gliadin (R7001) |
| 16 | negative | <5 | positive | 41 | positive | 750 | Gluten | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 17 | negative | <3 | positive | 21,9 | - | | Given as | RS | Ridascreen Gluten (R7001), r-Biopharm |
| 10 | negative | < 5 ppm | positive | 61,4 ppm | positive | | Gluten | VT | Veratox Gliadin R5, Neogen |
| 16 | negative | <10 | positive | 67 | - | - | Gluten | VT | Veratox Gliadin, Neogen |

Methods :

AQ = AgraQuant, RomerLabs
 IL = Immunolab

RS = Ridascreen®, R-Biopharm
 VT = Veratox, Neogen

Other details to the methods

| Evaluation number | Meth. Abr. | Specificity | Remarks to the Method (Extraction and Determination) | Further Remarks |
|-------------------|------------|----------------------|--|--|
| | | Antibody | e.g. Extraction Solution / Time / Temperature | |
| 7 | AQ | | | |
| 14 | IL | | | |
| 1 | RS | As stated in the kit | As per kit instructions | Sample solidified upon addition of primary extraction solution. To produce a liquid mix, half the amount of secondary extraction solution was added 1 stage early and the remaining amount of solution was added at the secondary stage. |
| 2 | RS | | Cocktail solution | |
| 3 | RS | | | |
| 4 | RS | R5 | | |
| 6 | RS | | | |
| 8 | RS | R5-Mendez | Cocktail solution/40min/50°C+ Ethanol80%/1 hour/room temperature | |
| 9 | RS | | | |
| 12 | RS | Gliadin | Cocktail-Lösung Art. Nr. R7006 / 60 min / 25°C | Spiking sample: 1:4000; sample A/B: 1:500; |
| 13 | RS | Gluten (R5) | Cocktail solution / 40 min / 50C | |
| 15 | RS | | As per kit instructions | |
| 16 | RS | | | |
| 17 | RS | | | |
| 10 | VT | Gliadin | | |
| 16 | VT | | | |

5.1.4 PCR: Gluten-containing Cereals*Primary data*

| Evaluation number | Result Sample A | | Result Sample B | | Result Spiking Sample | | quantitative Result given as | Meth. Abr. | Method |
|-------------------|-----------------|-------|-----------------|-------|-----------------------|-------|--------------------------------|------------|---|
| | qualitative | mg/kg | qualitative | mg/kg | qualitative | mg/kg | | | |
| 3 | positive | | positive | | positive | | Gluten | SFA | Sure Food Allergen, Congen / r-Biopharm |
| 17 | negative | | positive | | | | | SFA | Sure Food Allergen, Congen / r-Biopharm |
| 16 | negative | - | positive | - | positive | - | Wheat-DNA, Rye-DNA, Barley-DNA | div | internal method |

Method:

SFA = Sure Food Allergen,
R-Biopharm / Congen

div = not indicated / other method

Other Remarks to the Methods

| Evaluation number | Meth. Abr. | Specificity | Remarks to the Method (Extraction and Determination) | Further Remarks |
|-------------------|------------|-------------|--|-----------------|
| | | Antibody | e.g. Extraction / Enzymes / Clean-Up / Real Time PCR / Gel electrophoresis / Cycles | |
| 3 | SFA | | | |
| 17 | SFA | | | |
| 16 | div | | CTAB / Protease K / Chloroform + Promega Wizard/ End Point PCR/ 4% Agarose gel / 45 Cycles | |

5.2 Homogeneity

5.2.1 Mixture homogeneity before bottling

Microtracer Homogeneity Test

Spiking Material Sample

| | | |
|---------------------|--------------|-------|
| Weight whole sample | 1,21 | kg |
| Microtracer | FSS-rot lake | |
| Particle size | 75 – 300 | µm |
| Weight per particle | 2,0 | µg |
| Addition of tracer | 35,8 | mg/kg |

Result of analysis

| Sample | Weight [g] | Particle number | Particles [mg/kg] |
|--------|------------|-----------------|-------------------|
| 1 | 6,41 | 123 | 38,4 |
| 2 | 5,33 | 101 | 37,9 |
| 3 | 5,99 | 92 | 30,7 |
| 4 | 6,16 | 97 | 31,5 |
| 5 | 5,96 | 92 | 30,9 |
| 6 | 5,55 | 106 | 38,2 |
| 7 | 5,77 | 102 | 35,4 |
| 8 | 5,80 | 108 | 37,2 |

Poisson distribution

| | | |
|------------------------|-----------|----------|
| Number of samples | 8 | |
| Degree of freedom | 7 | |
| Mean | 102,8 | Partikel |
| Standard deviation | 10,1 | Partikel |
| χ^2 (CHI-Quadrat) | 6,95 | |
| Probability | 43 | % |
| Recovery rate | 98 | % |

Normal distribution

| | | |
|----------------------------|------------|-------|
| Number of samples | 8 | |
| Mean | 35,0 | mg/kg |
| Standard deviation | 3,44 | mg/kg |
| rel. Standard deviation | 9,82 | % |
| Horwitz standard deviation | 9,37 | % |
| HorRat-value | 1,0 | |
| Recovery rate | 98 | % |

Microtracer Homogeneity Test

DLA 03-2016 Sample B

| | | |
|---------------------|--------------|-------|
| Weight whole sample | 2,07 | kg |
| Microtracer | FSS-rot lake | |
| Particle size | 75 – 300 | µm |
| Weight per particle | 2,0 | µg |
| Addition of tracer | 19,6 | mg/kg |

Result of analysis

| Sample | Weight [g] | Particle number | Particles [mg/kg] |
|--------|------------|-----------------|-------------------|
| 1 | 6,6 | 67 | 20,5 |
| 2 | 5,9 | 55 | 18,7 |
| 3 | 5,7 | 45 | 15,8 |
| 4 | 6,8 | 49 | 14,5 |
| 5 | 6,1 | 53 | 17,4 |
| 6 | 6,8 | 55 | 16,1 |
| 7 | 6,2 | 59 | 19,1 |
| 8 | 5,5 | 39 | 14,2 |

Poisson distribution

| | | |
|------------------------|-----------|----------|
| Number of samples | 8 | |
| Degree of freedom | 7 | |
| Mean | 52,7 | Partikel |
| Standard deviation | 6,97 | Partikel |
| χ^2 (CHI-Quadrat) | 6,46 | |
| Probability | 49 | % |
| Recovery rate | 87 | % |

Normal distribution

| | | |
|----------------------------|------------|-------|
| Number of samples | 8 | |
| Mean | 17,0 | mg/kg |
| Standard deviation | 2,25 | mg/kg |
| rel. Standard deviation | 13,2 | % |
| Horwitz standard deviation | 10,4 | % |
| HorRat-value | 1,3 | |
| Recovery rate | 87 | % |

6. Index of participant laboratories

| Teilnehmer / Participant | Ort / Town | Land / Country |
|--------------------------|------------|----------------|
| | | SPAIN |
| | | FRANCE |
| | | CANADA |
| | | ITALY |
| | | Germany |
| | | Germany |
| | | Germany |
| | | Germany |
| | | SWEDEN |
| | | Germany |
| | | SPAIN |
| | | BELGIUM |
| | | GREAT BRITAIN |
| | | Germany |
| | | GREAT BRITAIN |
| | | Germany |
| | | Germany |

[Die Adressdaten der Teilnehmer wurden für die allgemeine Veröffentlichung des Auswertebereichs nicht angegeben.]

[The address data of the participants were deleted for publication of the evaluation report.]

7. Index of references

1. DIN EN ISO/IEC 17025:2005; Allgemeine Anforderungen an die Kompetenz von Prüf- und Kalibrierlaboratorien / General requirements for the competence of testing and calibration laboratories
2. DIN EN ISO/IEC 17043:2010; Konformitätsbewertung - Allgemeine Anforderungen an Eignungsprüfungen / Conformity assessment - General requirements for proficiency testing
3. ISO 13528:2015 & DIN ISO 13528:2009; Statistische Verfahren für Eignungsprüfungen durch Ringversuche / Statistical methods for use in proficiency testing by interlaboratory comparisons
4. ASU §64 LFGB: Planung und statistische Auswertung von Ringversuchen zur Methodvalidierung / DIN ISO 5725 series part 1, 2 and 6 Accuracy (trueness and precision) of measurement methods and results
5. Verordnung / Regulation 882/2004/EU; Verordnung über über amtliche Kontrollen zur Überprüfung der Einhaltung des Lebensmittel- und Futtermittelrechts sowie der Bestimmungen über Tiergesundheit und Tierschutz / Regulation on official controls performed to ensure the verification of compliance with feed and food law, animal health and animal welfare rules
6. Evaluation of analytical methods used for regulation of food and drugs; W. Horwitz; Analytical Chemistry, 54, 67-76 (1982)
7. The International Harmonised Protocol for the Proficiency Testing of Analytical Laboratories ; J.AOAC Int., 76(4), 926 - 940 (1993)
8. A Horwitz-like funktion describes precision in proficiency test; M. Thompson, P.J. Lowthian; Analyst, 120, 271-272 (1995)
9. Protocol for the design, conduct and interpretation of method performance studies; W. Horwitz; Pure & Applied Chemistry, 67, 331-343 (1995)
10. Recent trends in inter-laboratory precision at ppb and sub-ppb concentrations in relation to fitness for purpose criteria in proficiency testing; M. Thompson; Analyst, 125, 385-386 (2000)
11. The International Harmonised Protocol for the Proficiency Testing of Analytical Chemistry Laboratories; Pure Appl Chem, 78, 145 - 196 (2006)
12. AMC Kernel Density - Representing data distributions with kernel density estimates, amc technical brief, Editor M Thompson, Analytical Methods Committee, AMCTB No 4, Revised March 2006 and Excel Add-in Kernel.xla 1.0e by Royal Society of Chemistry
13. EURACHEM/CITAC Leitfaden, Ermittlung der Messunsicherheit bei analytischen Messungen (2003); Quantifying Uncertainty in Analytical Measurement (1999)
14. GMP+ Feed Certification scheme, Module: Feed Safety Assurance, chapter 5.7 Checking procedure for the process accuracy of compound feed with micro tracers in GMP+ BA2 Control of residues, Version: 1st of January 2015 GMP+ International B.V.
15. MTSE SOP No. 010.01 (2014): Quantitative measurement of mixing uniformity and carry-over in powder mixtures with the rotary detector technique, MTSE Micro Tracers Services Europe GmbH
16. Codex Alimentarius Commission (2010) - Guidelines on performance criteria and validation of methods for detection, identification and quantification of specific DNA sequences and specific proteins in foods, CAC/GL 74-2010
17. DIN EN ISO 15633-1:2009; Nachweis von Lebensmittelallergenen mit immunologischen Verfahren - Teil 1: Allgemeine Betrachtungen / Foodstuffs - Detection of food allergens by immunological methods - Part 1: General considerations
18. DIN EN ISO 15634-1:2009; Nachweis von Lebensmittelallergenen mit molekularbiologischen Verfahren - Teil 1: Allgemeine Betrachtungen / Foodstuffs - Detection of food allergens by molecular biological methods - Part 1: General considerations
19. DIN EN ISO 15842:2010 Lebensmittel - Nachweis von Lebensmittelallergenen - Allgemeine Betrachtungen und Validierung von Verfahren / Foodstuffs - Detection of food allergens - General considerations and validation of

- methods
20. Ministry of Health and Welfare, JSM, Japan 2006
 21. Working Group Food Allergens, Abbott et al., Validation Procedures for Quantitative Food Allergen ELISA Methods: Community Guidance and Best Practices JAOAC Int. 93:442-50 (2010)
 22. Working Group on Prolamin Analysis and Toxicity (WGPAT): Méndez et al. Report of a collaborative trial to investigate the performance of the R5 enzyme linked immunoassay to determine gliadin in gluten-free food. Eur J Gastroenterol Hepatol. 17:1053-63 (2005)
 23. DLA Publikation: Performance of ELISA and PCR methods for the determination of allergens in food: an evaluation of six years of proficiency testing for soy (*Glycine max* L.) and wheat gluten (*Triticum aestivum* L.); Scharf et al.; J Agric Food Chem. 61(43):10261-72 (2013)
 24. EFSA (2014) Scientific Opinion on the evaluation of allergenic foods and food ingredients for labelling purposes¹, EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), European Food Safety Authority (EFSA), Parma, Italy, EFSA Journal 2014;12(11):3894
 25. IRMM, Poms et al.; Inter-laboratory validation study of five different commercial ELISA test kits for determination of peanut residues in cookie and dark chocolate; European Commission, Joint Research Centre, Belgium; GE/R/FSQ/D08/05/2004
 26. Jayasena et al. (2015) Comparison of six commercial ELISA kits for their specificity and sensitivity in detecting different major peanut allergens. J Agric Food Chem. 2015 Feb 18;63(6):1849-55
 27. ASU §64 LFGB L 06.00-56 Bestimmung von Sojaprotein in Fleisch und Fleischerzeugnissen Enzymimmunologisches Verfahren (2007)
 28. ASU §64 LFGB L 00.00-69 Bestimmung von Erdnuss-Kontaminationen in Lebensmitteln mittels ELISA im Mikrotiterplattensystem (2003)
 29. ASU §64 LFGB L 44.00-7 Bestimmung von Haselnuss-Kontaminationen in Schokolade und Schokoladenwaren mittels ELISA im Mikrotiterplattensystem (2006)
 30. Šturm et al.; Enzyme-Linked Immunosorbent Assay Kit for Beta-Lactoglobulin Determination: Interlaboratory Study, JAOAC 92:1519-25 (2009)
 31. Šturm et al.; ELISA Kit for Casein Determination: Interlaboratory Study, JAOAC 93:676-682 (2010)